Experimental model and novel therapeutic targets for non-alcoholic fatty liver disease development.
Drug targeting
Hepatitis
Metabolic syndrome
Non-alcoholic fatty liver disease
Journal
The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology
ISSN: 1226-4512
Titre abrégé: Korean J Physiol Pharmacol
Pays: Korea (South)
ID NLM: 9709505
Informations de publication
Date de publication:
01 Jul 2023
01 Jul 2023
Historique:
received:
20
04
2023
revised:
18
05
2023
accepted:
19
05
2023
medline:
30
6
2023
pubmed:
30
6
2023
entrez:
30
6
2023
Statut:
ppublish
Résumé
Non-alcoholic fatty liver disease (NAFLD) is a complex disorder characterized by the accumulation of fat in the liver in the absence of excessive alcohol consumption. It is one of the most common liver diseases worldwide, affecting approximately 25% of the global population. It is closely associated with obesity, type 2 diabetes, and metabolic syndrome. Moreover, NAFLD can progress to non-alcoholic steatohepatitis, which can cause liver cirrhosis, liver failure, and hepatocellular carcinoma. Currently, there are no approved drugs for the treatment of NAFLD. Therefore, the development of effective drugs is essential for NAFLD treatment. In this article, we discuss the experimental models and novel therapeutic targets for NAFLD. Additionally, we propose new strategies for the development of drugs for NAFLD.
Identifiants
pubmed: 37386828
pii: kjpp.2023.27.4.299
doi: 10.4196/kjpp.2023.27.4.299
pmc: PMC10316197
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
299-310Références
Nutr Metab Cardiovasc Dis. 2022 Oct;32(10):2279-2288
pubmed: 35970684
Metabolism. 2018 Apr;81:13-24
pubmed: 29106945
Metabolism. 2019 Mar;92:82-97
pubmed: 30502373
J Hepatol. 2023 Apr 14;:
pubmed: 37061196
Int J Mol Sci. 2019 Jan 17;20(2):
pubmed: 30658440
J Biol Chem. 2011 Jan 14;286(2):1157-64
pubmed: 21081500
Life Sci. 2021 Feb 1;266:118868
pubmed: 33310034
Lipids Health Dis. 2017 Oct 16;16(1):203
pubmed: 29037210
Eur J Pharmacol. 2019 Apr 5;848:39-48
pubmed: 30689995
Sci Rep. 2022 Apr 29;12(1):7022
pubmed: 35487948
Arch Pharm Res. 2020 Aug;43(8):773-787
pubmed: 32839835
Nutrients. 2022 Jul 25;14(15):
pubmed: 35893906
Liver Int. 2020 Jun;40(6):1378-1394
pubmed: 32145145
J Endocrinol. 2020 Jun;245(3):425-437
pubmed: 32302970
Mol Cell Endocrinol. 2011 Jan 1;331(1):102-8
pubmed: 20797423
Biomed Pharmacother. 2020 Nov;131:110785
pubmed: 33152943
Gene Expr. 2018 Mar 21;18(1):5-17
pubmed: 29096730
J Food Drug Anal. 2021 Jun 15;29(2):240-254
pubmed: 35696209
Oncotarget. 2017 Dec 14;9(6):7204-7218
pubmed: 29467962
Front Physiol. 2021 Aug 30;12:710420
pubmed: 34526911
Diabetes. 2019 Jun;68(6):1099-1108
pubmed: 31109939
Acta Anaesthesiol Scand. 1984 Apr;28(2):182-4
pubmed: 6375235
J Hepatol. 2018 Aug;69(2):385-395
pubmed: 29572095
J Ethnopharmacol. 2021 Sep 15;277:114251
pubmed: 34052350
Metabolism. 2022 Nov;136:155248
pubmed: 35803320
Life Sci. 2022 Nov 15;309:120973
pubmed: 36150463
Diabetes Metab J. 2021 May;45(3):417-429
pubmed: 33705650
Nat Metab. 2020 Oct;2(10):1034-1045
pubmed: 32839596
Mar Drugs. 2021 Mar 12;19(3):
pubmed: 33809062
Nutr Res. 2021 Jul;91:26-35
pubmed: 34130208
World J Gastroenterol. 2018 Jul 7;24(25):2661-2672
pubmed: 29991872
Hepatology. 2021 Oct;74(4):1884-1901
pubmed: 33973269
Life Sci. 2021 Apr 1;270:119071
pubmed: 33515562
J Transl Med. 2022 Jul 30;20(1):341
pubmed: 35907871
Korean J Physiol Pharmacol. 2022 Nov 1;26(6):541-556
pubmed: 36302628
Arch Pharm Res. 2021 Jul;44(7):702-712
pubmed: 34302638
Arch Pharm Res. 2022 Dec;45(12):938-963
pubmed: 36441472
Int J Endocrinol. 2019 Jul 28;2019:7514802
pubmed: 31467529
Oncol Rep. 2015 Apr;33(4):1657-66
pubmed: 25607821
J Clin Invest. 2021 Oct 15;131(20):
pubmed: 34651580
Life Sci. 2022 Nov 1;308:120956
pubmed: 36103959
Arch Pharm Res. 2022 Nov;45(11):761-794
pubmed: 36318445
Int J Mol Sci. 2022 Jun 15;23(12):
pubmed: 35743140
Front Pharmacol. 2020 Dec 03;11:603926
pubmed: 33343375
Oxid Med Cell Longev. 2018 Jul 22;2018:8597897
pubmed: 30140371
Adv Drug Deliv Rev. 2021 Sep;176:113869
pubmed: 34280515
J Hepatol. 2021 Dec;75(6):1476-1484
pubmed: 34453963
Metabolism. 2021 Jul;120:154797
pubmed: 33984334
Nutrients. 2017 Sep 06;9(9):
pubmed: 28878197
Oxid Med Cell Longev. 2019 Dec 04;2019:4168380
pubmed: 31885789
Biomed Res Int. 2022 Jul 5;2022:4801695
pubmed: 35837380
Nat Commun. 2021 Jan 8;12(1):187
pubmed: 33420074
Cardiovasc Diabetol. 2021 Sep 15;20(1):189
pubmed: 34526024
J Biol Chem. 2021 Jan-Jun;296:100714
pubmed: 33930463
Cell Metab. 2021 Oct 5;33(10):2004-2020.e9
pubmed: 34614409
Crit Rev Clin Lab Sci. 2020 Aug;57(5):308-322
pubmed: 31935149
Drug Metab Dispos. 2018 Sep;46(9):1310-1319
pubmed: 29959134
Hepatology. 2021 Jul;74(1):116-132
pubmed: 33236445
Nutrients. 2022 Aug 08;14(15):
pubmed: 35956423
J Diabetes Res. 2023 Apr 15;2023:5891532
pubmed: 37096236
Obes Rev. 2023 Jun;24(6):e13563
pubmed: 36951144
Front Pharmacol. 2021 May 21;12:644129
pubmed: 34093184
Life Sci. 2023 May 15;321:121607
pubmed: 36958436
Gut. 2021 Apr;70(4):761-774
pubmed: 32694178
Int J Mol Sci. 2021 Jan 15;22(2):
pubmed: 33467546
Korean J Physiol Pharmacol. 2021 Sep 1;25(5):425-437
pubmed: 34448460
PLoS One. 2022 Feb 22;17(2):e0261310
pubmed: 35192632
World J Gastroenterol. 2019 Sep 14;25(34):5120-5133
pubmed: 31558861
J Hepatol. 2018 Apr;68(4):773-782
pubmed: 29273476
Int J Mol Sci. 2020 Jan 06;21(1):
pubmed: 31935815
Antioxidants (Basel). 2021 Apr 21;10(5):
pubmed: 33919415
Nutr Res Rev. 2023 Jun;36(1):120-139
pubmed: 35109946
Biochem Pharmacol. 2022 Jan;195:114845
pubmed: 34801522
Biomed Res Int. 2020 Jul 18;2020:4020249
pubmed: 32733940
Korean J Physiol Pharmacol. 2022 Nov 1;26(6):427-438
pubmed: 36302618
Int J Mol Sci. 2022 Feb 28;23(5):
pubmed: 35269812
Annu Rev Med. 2016;67:103-17
pubmed: 26473416
Nutrients. 2022 Feb 18;14(4):
pubmed: 35215504
Front Immunol. 2021 Feb 18;12:640869
pubmed: 33679803
Arch Pharm Res. 2021 Feb;44(2):241-252
pubmed: 33537886
JHEP Rep. 2021 Aug 08;3(6):100346
pubmed: 34667947
Front Immunol. 2018 Oct 18;9:2418
pubmed: 30405618
Nat Rev Mol Cell Biol. 2007 Oct;8(10):774-85
pubmed: 17712357
BMC Complement Med Ther. 2020 Jan 31;20(1):27
pubmed: 32020874
Mol Metab. 2020 May;35:100954
pubmed: 32244182
J Hepatol. 2021 Jan;74(1):156-167
pubmed: 32763266
Free Radic Biol Med. 2021 Feb 20;164:315-328
pubmed: 33429022
Arch Pharm Res. 2022 Nov;45(11):836-848
pubmed: 36401777
Biomed Pharmacother. 2021 Apr;136:111255
pubmed: 33485064
Korean J Physiol Pharmacol. 2021 Sep 1;25(5):403-411
pubmed: 34448458
JHEP Rep. 2020 Jan 02;2(1):100064
pubmed: 32039405
Arch Pharm Res. 2022 Mar;45(3):174-184
pubmed: 35325393
Hepatology. 2021 Apr;73(4):1327-1345
pubmed: 32567701
Cells. 2021 Nov 25;10(12):
pubmed: 34943814
Mol Metab. 2016 Jun 14;5(9):782-94
pubmed: 27617201
Science. 2020 Feb 7;367(6478):652-660
pubmed: 32029622
J Hepatol. 2015 Mar;62(3):720-33
pubmed: 25450203
Lung Cancer. 2018 Oct;124:233-240
pubmed: 30268467
Molecules. 2022 Aug 04;27(15):
pubmed: 35956917
Front Physiol. 2022 Feb 11;13:803445
pubmed: 35222075
Korean J Physiol Pharmacol. 2021 Sep 1;25(5):385-393
pubmed: 34448456
Nat Commun. 2020 Jul 3;11(1):3360
pubmed: 32620763
J Diabetes Res. 2020 Jul 31;2020:3920196
pubmed: 32832560